• 2009

Company Description

APIM Therapeutics is based on an original discovery by Prof. Marit Otterlei and co-inventors at the Department of Cancer Research and

APIM Therapeutics is based on an original discovery by Prof. Marit Otterlei and co-inventors at the Department of Cancer Research and Molecular Medicine at NTNU (Trondheim, Norway). The company is currently developing proprietary peptide drugs targeting PCNA (Proliferating Cell Nuclear Antigen), a key DNA repair protein regulating cellular responses to DNA damage and stress.

  • Manufacturer:

    Science and Engineering
  • Formed:

    2009
  • Company Website:

  • Company E-mail:

  • Company Address:

    c/o NTNU Technology Transfer AS, Sem Sælandsvei 14, Kjemiblokk 1, 3etg
    Trondheim
    Norway
  • CEO:

    • Konstantinos Alevizopoulos